Campos S - Search Results

1

Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer.

Campos S. Campos S. Oncologist. 2003;8 Suppl 2:10-6. doi: 10.1634/theoncologist.8-suppl_2-10. Oncologist. 2003. PMID: 13679591 Free article. Review.

2

The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.

Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, Seiden MV. Campos SM, et al. Gynecol Oncol. 2001 May;81(2):206-12. doi: 10.1006/gyno.2000.5980. Gynecol Oncol. 2001. PMID: 11330951

3

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.

Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Burstein HJ, et al. Among authors: campos sm. J Clin Oncol. 2001 May 15;19(10):2722-30. doi: 10.1200/JCO.2001.19.10.2722. J Clin Oncol. 2001. PMID: 11352965 Clinical Trial.

4

Hormonal therapy in postmenopausal women with breast cancer.

Campos SM, Winer EP. Campos SM, et al. Oncology. 2003;64(4):289-99. doi: 10.1159/000070284. Oncology. 2003. PMID: 12759523 Review.

5

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Burstein HJ, et al. J Clin Oncol. 2003 Aug 1;21(15):2889-95. doi: 10.1200/JCO.2003.02.018. J Clin Oncol. 2003. PMID: 12885806 Clinical Trial.

6

Aromatase inhibitors for breast cancer in postmenopausal women.

Campos SM. Campos SM. Oncologist. 2004;9(2):126-36. doi: 10.1634/theoncologist.9-2-126. Oncologist. 2004. PMID: 15047917 Free article. Review.

7

Evolving treatment approaches for early breast cancer.

Campos SM. Campos SM. Breast Cancer Res Treat. 2005;89 Suppl 1:S1-7. doi: 10.1007/s10549-005-0142-0. Breast Cancer Res Treat. 2005. PMID: 15770534 Review.

8

VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.

Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. Burstein HJ, et al. Clin Cancer Res. 2008 Dec 1;14(23):7871-7. doi: 10.1158/1078-0432.CCR-08-0593. Clin Cancer Res. 2008. PMID: 19047116 Clinical Trial.

9

Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer.

Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN. Campos SM, et al. Int J Clin Oncol. 2010 Aug;15(4):390-8. doi: 10.1007/s10147-010-0073-6. Epub 2010 Apr 20. Int J Clin Oncol. 2010. PMID: 20405155 Clinical Trial.

10

Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.

Lee EK, Xiong N, Cheng SC, Barry WT, Penson RT, Konstantinopoulos PA, Hoffman MA, Horowitz N, Dizon DS, Stover EH, Wright AA, Campos SM, Krasner C, Morrissey S, Whalen C, Quinn R, Matulonis UA, Liu JF. Lee EK, et al. Among authors: campos sm. Gynecol Oncol. 2020 Oct;159(1):72-78. doi: 10.1016/j.ygyno.2020.07.028. Epub 2020 Aug 6. Gynecol Oncol. 2020. PMID: 32771276 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

880 results

Search Page

Filters